Dr Mark Birrell is a Research lecturer in the Respiratory Pharmacology Research Group.
Mark obtained a BSc (Hons) Degree in Pharmacology from the University of East London whilst working at a major pharmaceutical company, Sanofi-Aventis. During his 15 years in industry Mark has had extensive experience in various phases of drug discovery. The therapeutic aim was to develop new medicine for initially cardiovascular diseases and then later respiratory diseases. He left industry in 2000 to help set up a new section, Respiratory Pharmacology, at the NHLI with Professor Belvisi. In the first 3 years he also obtained his doctorate in pharmacology at Imperial College.
Since completing his PhD, Mark has become a key member of the ever growing Respiratory Pharmacology research group, which he now runs with Professor Maria Belvisi.
Mark has a substantial publication record in peer review journals and is an internationally recognised expert in the respiratory field, particularly in pre-clinical models of asthma and COPD.
et al., 2008, Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages, Journal of Cellular Physiology, Vol:214, ISSN:0021-9541, Pages:27-37
et al., 2013, Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor, British Journal of Pharmacology, Vol:168, ISSN:0007-1188, Pages:129-138
et al., 2010, House dust mite induces direct airway inflammation in vivo: implications for future disease therapy?, European Respiratory Journal, Vol:35, ISSN:0903-1936, Pages:1377-1387
et al., 2011, EP4 receptor as a new target for bronchodilator therapy, Thorax, Vol:66, ISSN:0040-6376, Pages:1029-1035
et al., 2012, Transient receptor potential channels mediate the tussive response to prostaglandin E-2 and bradykinin, Thorax, Vol:67, ISSN:0040-6376, Pages:891-900